Methionine aminopeptidase type-2 inhibitors targeting angiogenesis

Current Topics in Medicinal Chemistry

Volumn 16, Issue 13, 2016, Pages 1478-1488

  Ehlers, Tedman ^b   Furness, Scott ^c   Robinson, Thomas Philip ^d   Zhong, Haizhen A ^e   Goldsmith, David ^f   Aribser, Jack ^g   Bowen, J Phillip ^a  

^a MERCER UNIVERSITY   (United States)

^b DASSAULT SYSTÈMES   (France)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

^e UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^f EMORY UNIVERSITY   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADME; Angiogenesis; Angiogenic inhibitors; Anti angiogenic compounds; Cancer; Drug design; Fumagillin; MetAP 2; Methionine aminiopeptidase; Ovalicin; Pharmacophore; TNP 470

Indexed keywords

BELORANIB; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; METHIONYL AMINOPEPTIDASE 2; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; ZGN 440; AMINOPEPTIDASE; CYCLOHEXANE DERIVATIVE; ENZYME INHIBITOR; GLYCOPROTEIN; METAP2 PROTEIN, HUMAN; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; SESQUITERPENE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; BIOLOGICAL ACTIVITY; CARCINOMA; CELL MIGRATION; CELL PROLIFERATION; DRUG DESIGN; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE TARGETING; HUMAN; IC50; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION; X RAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CONFORMATION; DRUG EFFECTS; METABOLISM; MOLECULAR MODEL; NEOVASCULARIZATION, PATHOLOGIC;

AMINOPEPTIDASES; ANIMALS; CELL PROLIFERATION; CYCLOHEXANES; ENZYME INHIBITORS; GLYCOPROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES;

EID: 84961684977     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150915121204     Document Type: Article

References (61)

1. Baguley, B.C. In: Anticancer Drug Development; Baguley, B. C.; Kerr, D. J., Eds.; Academic Press, San Diego, 2002; pp. 1-11.
2. Brody, T.M.; Larner, M.; Minneman, K.P.; Neu, H.C. Human Pharmacology: Molecular to Clinical, 2nd ed.; Mosby: St. Louis, 1994.
3. Barrett, J.F.; Isaacson, R.E. In: Annual Rep. Med. Chem. Bristol J. A., Ed. Academic Press, San Diego, 1995, pp. 111-118.
4. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972, 175, 409-416.
5. Liekens, S.; De Clercq, E.; Neyts, J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol., 2001, 61, 253-270.
6. Papetti, M.; Herman, I.M. Mechanisms of normal and tumorderived angiogenesis. Am. J. Physiol.-Cell Physiol., 2002, 282, C947-C970.
7. Folkman, J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med., 1995, 333, 1757-1763.
8. Folkman, J.; Bach, M.; Rowe, J.W.; Davidoff, F.; Lambert, P.; Hirsch, C.; Goldberg, A.; Hiatt, H.H.; Glass, J.; Henshaw, E. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285, 1182-1186.
9. Ingber, D.; Fujita, T.; Kishimoto, S.; Sudo, K.; Kanamaru, T.; Brem, H.; Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature, 1990, 348, 555-557.
10. Kusaka, M.; Sudo, K.; Fujita, T.; Marui, S.; Itoh, F.; Ingber, D.; Folkman, J. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun., 1991, 174, 1070-1076.
11. Eble, T E.; Hanson, F.R. Fumagillin, an antibiotic from Aspergillus fumigatus H-3. Antibiot. Chemother., 1951, 1, 54-58.
12. Ingber, D.; Fujita, T.; Kishimoto, S.; Sudo, K.; Kanamaru, T.; Brem, H.; Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature, 1990, 348, 555-557.
13. Sin, N.; Meng, L.; Wang, M.Q.; Wen, J.J.; Bornmann, W.G.; and Crews, C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 6099-6103.
14. Turk, B.E.; Su, Z.; Liu, J.O. Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Bioorg. Med. Chem., 1998, 6, 1163-1169.
15. Bhandarkar, S.S.; Bromberg, J.; Carrillo, C.; Selvakumar, P.; Sharma, R.K.; Perry, B.N.; Govindarajan, B.; Fried, L.; Sohn, A.; Reddy, K.; Arbiser, J.L. Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo. Clin. Cancer Res., 2008, 14, 5743-5748.
16. Klauber, N.; Rohan, R.M.; Flynn, E.; D'Amato, R.J. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat. Med., 1997, 3, 443-446.
17. Griffith, E.C.; Su, Z.; Turk, B.E.; Chen, S.; Chang, Y.H.; Wu, Z.; Biemann, K.; Liu, J.O. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol., 1997, 4, 461-471.
18. Boehm, T.; Folkman, J.; Browder, T.; O’Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 1997, 390, 404-407.
19. Furness, M.S.; Robinson, T.P.; Ehlers, T.; Hubbard, R. B., IV; Arbiser, J. L., Goldsmith, D.J.; Bowen, J.P. Antiangiogenic Agents: Studies of Fumagillin and Curcumin Analogs. Curr. Pharm Des., 2005, 111, 357-373.
20. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res., 2000, 28, 235-242.
21. Liu, S.; Widom, J.; Kemp, C.W.; Crews, C.M.; Clardy, J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science, 1998, 282, 1324-1327.
22. Marino, J.P. Jr.; Fisher, P.W.; Hofmann, G.A.; Kirkpatrick, R.B.; Janson, C.A.; Johnson, R.K.; Ma, C.; Mattern, M.; Meek, T.D.; Ryan, M.D.; Schulz, C.; Smith, W.W.; Tew, D.G.; Tomazek, T.A. Jr.; Veber, D.F.; Xiong, W.C.; Yamamoto, Y.; Yamashita, K.; Yang, G.; Thompson, S.K. Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore. J. Med. Chem., 2007, 50, 3777-3785.
23. Nonato, M.C.; Widom, J.; Clardy, J. Human methionine aminopeptidase type 2 in complex with L- and D-methionine. Bioorg. Med. Chem. Lett., 2006, 16, 2580-2583.
24. Sheppard, G.S.; Wang, J.; Kawai, M.; Fidanze, S.D.; BaMaung, N.Y.; Erickson, S.A.; Barnes, D.M.; Tedrow, J.S.; Kolaczkowski, L.; Vasudevan, A.; Park, D.C.; Wang, G.T.; Sanders, W.J.; Mantei, R.A.; Palazzo, F.; Tucker-Garcia, L.; Lou, P.; Zhang, Q.; Park, C.H.; Kim, K.H.; Petros, A.; Olejniczak, E.; Nettesheim, D.; Hajduk, P.; Henkin, J.; Lesniewski, R.; Davidsen, S.K.; Bell, R.L. Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding. J. Med. Chem., 2006, 49, 3832-3849.
25. Wang, G.T.; Mantei, R.A.; Kawai, M.; Tedrow, J.S.; Barnes, D.M.; Wang, J.; Zhang, Q.; Lou, P.; Garcia, L.A.; Bouska, J.; Yates, M.; Park, C.; Judge, R.A.; Lesniewski, R.; Sheppard, G.S.; Bell, R.L. Lead optimization of methionine aminopeptidase-2 (MetAP2) inhibitors containing sulfonamides of 5,6-disubstituted anthranilic acids. Bioorg. Med. Chem. Lett., 2007, 17, 2817-2822.
26. Alvarado, J.J.; Nemkal, A.; Sauder, J.M.; Russell, M.; Akiyoshi, D.E.; Shi, W.; Almo, S.C.; Weiss, L M. Structure of a microsporidian methionine aminopeptidase type 2 complexed with fumagillin and TNP-470. Mol. Biochem. Parasitol., 2009, 168, 158-167.
27. D'souza, V.M.; Holz, R.C. The methionyl aminopeptidase from Escherichia coli can function as an iron(II) enzyme. Biochemistry, 1999, 38, 11079-11085.
28. Leopoldini, M.; Russo, N.; Toscano, M. Which one among Zn(II), Co(II), Mn(II), and Fe(II) is the most efficient ion for the methionine aminopeptidase catalyzed reaction? J. Am. Chem. Soc., 2007, 129, 7776-7784.
29. Addlagatta, A.; Hu, X.; Liu, J.O.; Matthews, B.W. Structural basis for the functional differences between type I and type II human methionine aminopeptidases. Biochemistry, 2005, 44, 14741-14749.
30. Turk, B.E.; Griffith, E.C.; Wolf, S.; Biemann, K.; Chang, Y.H.; Liu, J.O. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem. Biol., 1999, 6, 823-833.
31. Zhang, Y.; Griffith, E.C.; Sage, J.; Jacks, T.; Liu, J.O. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 6427-6432.
32. Kawai, M.; BaMaung, N.Y.; Fidanze, S.D.; Erickson, S.A.; Tedrow, J.S.; Sanders, W.J.; Vasudevan, A.; Park, C.; Hutchins, C.; Comess, K.M.; Kalvin, D.; Wang, J.; Zhang, Q.; Lou, P.; Tucker- Garcia, L.; Bouska, J.; Bell, R.L.; Lesniewski, R.; Henkin, J.; Sheppard, G.S. Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg. Med. Chem. Lett., 2006, 16, 3574-3577.
33. Zhou, Y.; Zhao, Y.; O'Boyle, K.M.; Murphy, P.V. Hybrid angiogenesis inhibitors: Synthesis and biological evaluation of bifunctional compounds based on 1-deoxynojirimycin and aryl-1,2,3- triazoles. Bioorg. Med. Chem. Lett., 2008, 18, 954-958.
34. Chong, C. R.; Xu, J.; Lu, J.; Bhat, S.; Sullivan, D.J. Jr.; Liu, J.O. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem. Biol., 2007, 2, 263-270.
35. Sheppard, G.S.; Wang, J.; Kawai, M.; BaMaung, N.Y.; Craig, R.A.; Erickson, S.A.; Lynch, L.; Patel, J.; Yang, F.; Searle, X.B.; Lou, P.; Park, C.; Kim, K.H.; Henkin, J.; Lesniewski, R. 3-Amino- 2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2. Bioorg. Med. Chem. Lett., 2004, 14, 865-868.
36. Wang, J.; Tucker, L.A.; Stavropoulos, J.; Zhang, Q.; Wang, Y.C.; Bukofzer, G.; Niquette, A.; Meulbroek, J.A.; Barnes, D.M.; Shen, J.; Bouska, J.; Donawho, C.; Sheppard, G.S.; Bell, R.L. Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 1838-1843.
37. Selvakumar, P.; Lakshmikuttyamma, A.; Das, U.; Pati, H.N.; Dimmock, J.R.; Sharma, R.K. NC2213: a novel methionine aminopeptidase 2 inhibitor in human colon cancer HT29 cells. Mol. Cancer, 2009, 8, 65.
38. Chai, S.C.; Ye, Q.Z. Metal-mediated inhibition is a viable approach for inhibiting cellular methionine aminopeptidase. Bioorg. Med. Chem. Lett., 2009, 19, 6862-6864.
39. Arico-Muendel, C.; Centrella, P.A.; Contonio, B.D.; Morgan, B.A.; O'Donovan, G.; Paradise, C.L.; Skinner, S.R.; Sluboski, B.; Svendsen, J.L.; White, K.F.; Debnath, A.; Gut, J.; Wilson, N.; McKerrow, J.H.; DeRisi, J.L.; Rosenthal, P.J.; Chiang, P.K. Antiparasitic activities of novel, orally available fumagillin analogs. Bioorg. Med. Chem. Lett., 2009, 19, 5128-5131.
40. Arico-Muendel, C.C.; Benjamin, D.R.; Caiazzo, T.M.; Centrella, P.A.; Contonio, B.D.; Cook, C.M.; Doyle, E.G.; Hannig, G.; Labenski, M.T.; Searle, L.L.; Lind, K.; Morgan, B.A.; Olson, G.; Paradise, C.L.; Self, C.; Skinner, S.R.; Sluboski, B.; Svendsen, J.L.; Thompson, C.D.; Westlin, W.; White, K. F. Carbamate analogues of fumagillin as potent, targeted inhibitors of methionine aminopeptidase-2. J. Med. Chem. 2009, 52, 8047-8056.
41. Cooper, A.C.; Karp, R.M.; Clark, E.J.; Taghizadeh, N.R.; Hoyt, J.G.; Labenski, M. T.; Murray, M.J.; Hannig, G.; Westlin, W.F.; Thompson, C.D. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo. Clin. Cancer Res., 2006, 12, 2583-2590.
42. Hannig, G.; Lazarus, D.D.; Bernier, S.G.; Karp, R.M.; Lorusso, J.; Qiu, D.; Labenski, M.T.; Wakefield, J.D.; Thompson, C.D.; Westlin, W.F. Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458. Int. J. Oncol., 2006, 28, 955-963.
43. Lazarus, D.D.; Doyle, E.G.; Bernier, S.G.; Rogers, A.B.; Labenski, M.T.; Wakefield, J.D.; Karp, R.M.; Clark, E.J.; Lorusso, J.; Hoyt, J.G.; Thompson, C.D.; Hannig, G.; Westlin, W.F. An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis. Inflamm. Res., 2008, 57, 18-27.
44. Bernier, S.G.; Lazarus, D.D; Clark, E.; Doyle, B.; Labenski, M.T.; Thompson, C.D.; Westlin, W.F.; Hannig, G. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 10768-10773.
45. The clinical trials website: http://clinicaltrials.gov (Accessed August 24, 2015).
46. Asami, Y.; Kakeya, H.; Onose, R.; Chang, Y.-H.; Toi, M.; Osada, H. RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase- 2. Tetrahedron, 2004, 60, 7085-7091.
47. Accelrys Software Inc., Discovery Studio Modeling Environment, San Diego: Accelrys Software Inc., 2012.
48. Momany, F.A.; Rone, R. Validation of the general purpose QUANTA 3.2/CHARMm force field. J. Comput. Chem., 1992, 13, 888-900.
49. Cornell, W.D.; Cieplak, P.; Bayly, C.I.; Gould, I.R.; Merz, K.M.; Ferguson, D.M.; Spellmeyer, D.C.; Fox, T.; Caldwell, J.W.; Kollman, P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc., 1995, 117, 5179-5197.
50. Wang, J.M.; Cieplak, P.; Kollman, P.A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem., 2000, 21, 1049-1074.
51. Spassov, V.Z.; Yan, L. A fast and accurate computational approach to protein ionization. Protein Sci., 2008, 17, 1955-1970.
52. Dezube, B.J.; Von Roenn, J.H.; Holden-Wiltse, J.; Cheung, T.W.; Remick, S.C.; Cooley, T.P.; Moore, J.; Sommadossi, J.P.; Shriver, S.L.; Suckow, C.W.; Gill, P.S. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J. Clin. Oncol., 1998, 16, 1444-1449.
53. Kudelka, A.P.; Levy, T.; Verschraegen, C.F.; Edwards, C.L.; Piamsomboon, S.; Termrungruanglert, W.; Freedman, R.S.; Kaplan, A.L.; Kieback, D.G.; Meyers, C.A.; Jaeckle, K.A.; Loyer, E.; Steger, M.; Mante, R.; Mavligit, G.; Killian, A.; Tang, R.A.; Gutterman, J.U.; Kavanagh, J.J. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res., 1997, 9, 1501-1505
54. Satchi-Fainaro, R.; Mamluk, R.; Wang, L.; Short, S.M.; Nagy, J.A.; Feng, D.; Dvorak, A.M.; Dvorak, H.F.; Puder, M.; Mukhopadhyay, D.; Folkman, J. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell, 2005, 7, 251-261.
55. Stadler, W.M.; Kuzel, T.; Shapiro, C.; Sosman, J.; Clark, J.; Vogelzang, N.J. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol., 1999, 17, 2541-2545.
56. Logothetis, C.J.; Wu, K.K.; Finn, L.D.; Daliani, D.; Figg, W.; Ghaddar, H.; Gutterman, J.U. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res., 2001, 7, 1198-1203.
57. Lee, H.W.; Cho, C.S.; Kang, S.K.; Yoo, Y.S.; Shin, J.S.; Ahn, S.K. Design, synthesis, and antiangiogenic effects of a series of potent novel fumagillin analogues. Chem. Pharm. Bull. (Tokyo), 2007, 55, 1024-1029.
58. Kim, E.J.; Shin, W.H. General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Biol. Pharm. Bull., 2005, 28, 217.
59. Morowitz, M.J.; Barr, R.; Wang, Q.; King, R.; Rhodin, N.; Pawel, B.; Zhao, H.; Erickson, S.A.; Sheppard, G.S.; Wang, J.; Maris, J.M.; Shusterman, S. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin. Cancer Res., 2005, 11, 2680.
60. Herbst, R.S.; Madden, T.L.; Tran, H.T.; Blumenschein, G.R., Jr.; Meyers, C.A.; Seabrooke, L.F.; Khuri, F.R.; Puduvalli, V.K.; Allgood, V.; Fritsche, H.A., Jr.; Hinton, L.; Newman, R.A.; Crane, E.A.; Fossella, F.V.; Dordal, M.; Goodin, T.; Hong, W.K. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol., 2002, 20, 4440-4447.
61. Tran, H.T.; Blumenschein, G.R., Jr.; Lu, C.; Meyers, C.A.; Papadimitrakopoulou, V.; Fossella, F.V.; Zinner, R.; Madden, T.; Smythe, L.G.; Puduvalli, V.K.; Munden, R.; Truong, M.; Herbst, R.S. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother. Pharmacol., 2004, 54, 308-314.